drugset / Trial / NCT07128082
The Long COVID Treatment Trial
Phase 2
Active not recruiting
1000 enrolled
Scripps Translational Science Institute
Schmidt Initiative for Long COVID · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The goal of this study is to determine whether a medicine called tirzepatide, also called Zepbound, can reduce symptoms of Long COVID. A randomized control trial will allow us to measure the effect of the treatment by having half of the participants take the medication and half take a placebo that has no medication. Participants will take the medication (or placebo) they are given and complete study surveys for 12 months. All of the study tasks are done remotely from the comfort of a participants home.
Timeline
- Start
- 2025-10-30
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Tirzepatide | Peptide | 2.5 mg | — |